<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present five cases of concomitant relapsed <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and therapy related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>After treatment with thalidomide marked anti-<z:mp ids='MP_0009440'>myeloma</z:mp> activity was observed, but it was associated with <z:hpo ids='HP_0003678'>rapid progression</z:hpo> of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>This paradoxical effect of thalidomide is concerning because there is increasing use of thalidomide in relapsed, heavily treated <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> patients who already have a higher propensity to develop <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The leukemic transformation in our cases most probably reflects the natural progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, though it clearly demonstrates that thalidomide is ineffective in controlling blast proliferation in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>More concerning, however, is the possibility that thalidomide, while suppressing the <z:mp ids='MP_0009440'>myeloma</z:mp> clone, eliminates inhibitory signals and subsequently stimulates the proliferation of the leukemic clone </plain></SENT>
<SENT sid="5" pm="."><plain>The use of thalidomide should be carefully assessed in relapsed <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> patients with clinical and cytogenetic evidence of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>